1798792-42-3Relevant articles and documents
Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis
Hopkins, Brian T.,Bame, Eris,Bajrami, Bekim,Black, Cheryl,Bohnert, Tonika,Boiselle, Carrie,Burdette, Doug,Burns, Jeremy C.,Delva, Luisette,Donaldson, Douglas,Grater, Richard,Gu, Chungang,Hoemberger, Marc,Johnson, Josh,Kapadnis, Sudarshan,King, Kris,Lulla, Mukesh,Ma, Bin,Marx, Isaac,Magee, Tom,Meissner, Robert,Metrick, Claire M.,Mingueneau, Michael,Murugan, Paramasivam,Otipoby, Kevin L.,Polack, Evelyne,Poreci, Urjana,Prince, Robin,Roach, Allie M.,Rowbottom, Chris,Santoro, Joseph C.,Schroeder, Patricia,Tang, Hao,Tien, Eric,Zhang, Fengmei,Lyssikatos, Joseph
supporting information, p. 1206 - 1224 (2021/11/18)
Multiple Sclerosis is a chronic autoimmune neurodegenerative disorder of the central nervous system (CNS) that is characterized by inflammation, demyelination, and axonal injury leading to permeant disability. In the early stage of MS, inflammation is the
BENZOAZEPINE ANALOGS AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE
-
Page/Page column 126; 128, (2018/11/10)
Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their production and compounds of formula (I) for use in treating a disease responsive to the inhibition of Bruton's tyrosine.
BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY
-
Paragraph 0499, (2015/06/25)
The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
